Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Moderate Buy” by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has earned a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $192.07.

Several equities analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. TD Cowen decreased their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Oppenheimer decreased their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective for the company.

Ascendis Pharma A/S Stock Up 2.5 %

Shares of NASDAQ:ASND opened at $134.87 on Thursday. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00. The company has a 50 day moving average of $132.84 and a two-hundred day moving average of $133.54. The company has a market capitalization of $8.19 billion, a price-to-earnings ratio of -16.69 and a beta of 0.65.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently made changes to their positions in ASND. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S in the third quarter worth approximately $30,000. Groupama Asset Managment bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $60,000. GAMMA Investing LLC raised its position in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the last quarter. Signaturefd LLC lifted its position in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.